Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

MELBOURNE, Australia, October 7 /PRNewswire/ -- Quintiq, a leading provider of Advanced Planning and Scheduling (APS) solutions, today announced that Dalrymple Bay Coal Terminal Pty Ltd. (DBCT P/L) has chosen Quintiq to provide a purpose-built APS solution to optimise its current capacity capabilities and support projected expansion over the next decade. Quintiq will implement the Quintiq Application Suite to fit DBCT's specific bulk commodities planning and scheduling needs and integrate with DBCT P/L's other IT systems.

ANTONY, France, October 7 /PRNewswire/ -- Stallergenes S.A. today announced that they have entered into an exclusive agreement with Catalent for the promotion and distribution in Europe of adrenaline autoinjector, ADREFLEX(R), co-developed and co-manufactured by Catalent and The Medical House PLC.

ADREFLEX(R) consists of a syringe pre-filled with adrenaline, which will be available for adult and paediatric use (0.3 and 0.15 mg), in an autoinjector device. The Medical House has designed this totally new device to improve the safety and the ease-of-use for patients.

PRINCETON, New Jersey, October 7 /PRNewswire/ --

Informex today announced that it will hold a Global Sourcing Summit for the Pharmaceutical Industry, November 10-11, at Princeton, New Jersey, USA. The two-day conference will address the next generation of operational and business strategies in the field of global pharmaceutical procurement. David Kinnear, President & CEO of the Global Sourcing Council, will chair the inaugural conference and host a panel of distinguished speakers with vision and insight into the future of global sourcing, including those from Johnson & Johnson, Bristol Myers Squibb, Genentech, Boehringer Ingelheim and Roche Molecular Diagnostics.

GENEVA, Switzerland, October 7 /PRNewswire/ -- When asked about the effect of the current financial crisis on currency markets, ACM Chief Market Analyst sounded very positive. From a trading perspective the "current crisis is actually bolstering our online trading activities" said Rosenstreich. "We are seeing a significant migration of investors, leaving the stock market and investing in the most appealing market of the moment; the Foreign Exchange Market.

Unlike any structured product, the FX spot market contains no hidden risk. Trading on the spot market implies buying or selling the so called "underlying" asset itself.

ATLANTA, October 7 /PRNewswire/ --

- Surgical Congress to focus on new patient data supporting the Ross heart reconstruction procedure and the use of SynerGraft processed human heart valves in the Ross procedure

BRUSSELS, October 7 /PRNewswire/ -- A key part of the EU's climate change policy - the Emission Trading System (ETS) - could destroy the economic viability of Europe's aluminium industry. The European Parliament's Environment Committee recognised the impact of CO2 costs passed into electricity prices (indirect effects) as one of the criteria for carbon leakage, as it has a large negative effect on the competitiveness of energy intensive industries. Therefore, it is inexplicable that the Committee failed to adopt provisions for a legal mechanism to address this problem.